Haemophilia is a serious, inherited bleeding disorder in which a person’s blood does not clot properly, in severe cases leading to uncontrolled bleeding, either spontaneously or after minor trauma.
Medical care for haemophilia A, the most well-known inherited bleeding disorder, is often restricted in developing countries. Left untreated, bleeds can lead to irreversible joint damage and intracranial bleeds, and potentially cause brain development problems which may be life-threatening. Roche is working closely with multiple partners to provide consistent and predictable access to preventative and on-demand treatment for bleeding disorders, for people in locations that need it most.
For more than 20 years, Roche has been innovating and delivering medicines for people with diseases of the blood. With the rise of novel therapies within haemophilia, we are working closely with all corners of the global haemophilia community – through our efforts to help improve the provision of treatments for those who need it most; through our dedication towards supporting patients at all stages of their haemophilia journey; and ultimately helping to transform the way haemophilia is treated and managed.
We are collaborating with the WFH to provide a novel prophylactic treatment to as many as 1,000 people with haemophilia A over five years in locations where there is little or no access to haemophilia treatment. In addition, Roche contributes to the WFH Humanitarian Aid Program integrated care development training, with funding to ensure local infrastructure and medical expertise are available to optimise and appropriately use the donated product.
By working toward a shared vision of Treatment for All, the WFH and all of its partners, including Roche, aim to address gaps in healthcare and bring innovative treatment solutions to patients living with haemophilia.
The formation of a blood clot is an important process that stops a person from bleeding. Meet "Team Clotting" and learn more about how the clotting cascade works by watching these interactive videos.
Learn about some of the key milestones in the development and engineering of monoclonal antibodies, and the role they play in haemophilia
Michael and Mirko share their different perspectives on living with haemophilia A.
The vital importance of raising awareness about women within the haemophilia community.
© 2023, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.
M-NZ-00000625-v6.0/MR9618/NOV23. This site was last updated NOV2023